Outlook Therapeutics, Inc.
OTLKOutlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of the first approved ophthalmic formulation of bevacizumab for retinal diseases.
Earnings
Next report
Dec 18, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of the first approved ophthalmic formulation of bevacizumab for retinal diseases. Its lead product, ONS-5010/LYTENAVA, is designed to treat wet age-related macular degeneration (wet AMD) as a regulated alternative to the common off-label use of repackaged intravenous bevacizumab. The company aims to capture significant market share in the global anti-VEGF retina market by providing a standardized, approved therapeutic option.
The company holds the first and only marketing authorization for an ophthalmic bevacizumab formulation in the EU and UK, positioning it as a regulated alternative to off-label repackaged cancer drugs.
FAQ
- What is Outlook Therapeutics, Inc.'s market cap?
- Outlook Therapeutics, Inc. (OTLK) has a market capitalization of $120.1M and trades on NASDAQ.
- Who are Outlook Therapeutics, Inc.'s competitors?
- Outlook Therapeutics, Inc.'s key competitors include Regeneron Pharmaceuticals, LENZ Therapeutics, Inc. Common Stock, Lineage Cell Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
- Who does Outlook Therapeutics, Inc. partner with?
- Outlook Therapeutics, Inc.'s notable partners include European Commission, Medicines and Healthcare products Regulatory Agency.
- Where is Outlook Therapeutics, Inc. headquartered?
- Outlook Therapeutics, Inc. is headquartered in United States of America and employs approximately 24 people. It has been publicly traded since 2016.